OBJECTIVE: To systematically evaluate the clinical efficacy of milinone as anti-heart failure drug in the treatment of persistent pulmonary hypertension of the newborn（ PPHN）

so as to provide reference for the evidence-based medicine and new treatment method.METHODS: PubMed

EMBase

Medline

the Cochrane Library

CNKI

VIP database

Wanfang database and CBM were retrieved to collect the randomized controlled trial（ RCT） of milrinone + conventional treatment（ study group） vs.conventional treatment（ control group） for PPHN.The retrieval time was from the establishment of the database to Oct.2019.The literature were screened

data were extracted and literature quality was evaluated according to the Jadad scale.Total response rate

pulmonary artery systolic pressure（ PASP）

arterial partial oxygen pressure（ PaO

2

） and oxygenation index（ OI） were analyzed by using RevMan 5.3 statistical software.RESULTS: Totally 12 literature were extracted

including 722 children.Meta-analysis showed that the total effective rate（ RD = 0.19

95%CI = 0.13-0.24

P

<

0.000 01） and PaO

2

（ MD = 10.54

95%CI = 6.89-14.19

P

<

0.000 01） of the study group were significantly higher than those of the control group

and PASP was significantly lower than that of the control group（ MD =-10.24

95% CI =-14.07--6.40

P

<

0.000 01）

the differences were statistically significant.There was no significant difference in OI between two groups（ MD =-0.83

95% CI =-5.92-4.26

P = 0.75

>

0.05）.CONCLUSIONS: The application of anti-heart failure drug milrinone can greatly improve the total clinical treatment efficiency and PaO

2

of children with PPHN

reduce the PASP

and greatly help to improve the quality of life of children.